Denikitug

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

HER2-NegativeAdvanced Microsatellite Stable Colorectal Cancer

4 competitors in HER2-Negative

#DrugCompanyPhaseTrials

1

Opdivo

Bristol-Myers Squibb

Phase 2

22

Cyramza

Eli Lilly

Phase 2

13

Taxol

Teva

Phase 2

14

Tuoyi

CCoherus Oncology, Inc.

Phase 2

15

Denikitug

Gilead

Phase 2

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Solid Tumor1 trial

A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors

Active, not recruiting·Gilead·Phase 1·NCT05007782·304 enrolled

HER2-Negative1 trial

A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

Recruiting·Gilead·Phase 2·NCT07546812·120 enrolled

Advanced Microsatellite Stable Colorectal Cancer1 trial

A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)

Recruiting·Gilead·Phase 2·NCT07527858·170 enrolled

Details

Drug Info

Related News